(in millions $) | 6 Nov 2023 | 7 Aug 2023 | 30 Jul 2023 | 27 Mar 2023 |
---|---|---|---|---|
Current assets | ||||
Cash | $13943.45 | $15038.35 | $14166.6 | $14533.37 |
Short term investments | $2929.65 | $2059.91 | $483.6 | |
Net receivables | $2068.41 | $2821.45 | $2995.4 | $7484.6 |
Inventory | $429.49 | $476.52 | $448.9 | $460.46 |
Total current assets | $19371 | $20396.23 | $19213.9 | $22962.03 |
Long term investments | $3572.8 | $3197.03 | $1421.48 | |
Property, plant & equipment | $753.08 | $733.63 | $894 | $638.1 |
Goodwill & intangible assets | ||||
Total noncurrent assets | ||||
Total investments | ||||
Total assets | $22943.8 | $23593.26 | $22225.6 | $24383.51 |
Current liabilities | ||||
Accounts payable | $230.09 | $242.67 | $228.6 | $213.78 |
Deferred revenue | ||||
Short long term debt | $41.33 | $40.98 | $37.71 | |
Total current liabilities | $1867.14 | $1930.93 | $1819 | $3090.58 |
Long term debt | $167.27 | $177.38 | $167.1 | $184.56 |
Total noncurrent liabilities | ||||
Total debt | ||||
Total liabilities | $2418.03 | $2461.81 | $2319.1 | $3376.43 |
Shareholders' equity | ||||
Retained earnings | $19945.75 | $20322.88 | $19666.7 | $19726.48 |
Other shareholder equity | ||||
Total shareholder equity | $20525.77 | $21131.45 | $21007.08 |
(in millions $) | 31 Jan 2023 | 30 Mar 2022 | 30 Dec 2020 | 30 Dec 2019 |
---|---|---|---|---|
Current assets | ||||
Cash | $13875.1 | $1715.46 | $1210.21 | $519.15 |
Short term investments | $483.6 | $502.06 | $137.23 | $1.68 |
Net receivables | $7146 | $12548.2 | $166.37 | $20.2 |
Inventory | $439.6 | $509.26 | $64.12 | $12.07 |
Total current assets | $21922 | $15274.98 | $1666.9 | $560.15 |
Long term investments | $1421.48 | $768.7 | ||
Property, plant & equipment | $821.1 | $326.84 | $325.96 | $148.06 |
Goodwill & intangible assets | ||||
Total noncurrent assets | $744.46 | $266 | ||
Total investments | ||||
Total assets | $23279.1 | $16043.68 | $2318.62 | $797.65 |
Current liabilities | ||||
Accounts payable | $204.1 | $162.15 | $102.29 | $20.5 |
Deferred revenue | ||||
Short long term debt | $37.71 | $131.65 | $3.02 | $1.82 |
Total current liabilities | $2950.6 | $3528.42 | $606.01 | $138.14 |
Long term debt | $176.2 | $173.91 | $153.02 | $14.78 |
Total noncurrent liabilities | $389.25 | $185.93 | ||
Total debt | $293.41 | $83.24 | ||
Total liabilities | $3223.5 | $3990.04 | $946.77 | $304.15 |
Shareholders' equity | ||||
Retained earnings | $19812.3 | $10015.8 | -$409.63 | -$424.83 |
Other shareholder equity | $1768.3 | $1539.95 | $691.54 | |
Total shareholder equity | $21007.08 | $12053.64 | $1371.85 | $493.49 |
(in millions $) | 6 Nov 2023 | 7 Aug 2023 | 30 Jul 2023 | 27 Mar 2023 |
---|---|---|---|---|
Revenue | ||||
Total revenue | $925 | $178.02 | $167.7 | $4609.67 |
Cost of revenue | $167.17 | $172.92 | $225.9 | |
Gross Profit | $757.83 | $5.1 | $4.8 | $4383.77 |
Operating activities | ||||
Research & development | $514.42 | $396.38 | $563.47 | |
Selling, general & administrative | $164.17 | $149.46 | $157.43 | |
Total operating expenses | $845.75 | $718.77 | $509.5 | $776.56 |
Operating income | $79.24 | -$540.75 | $3833.11 | |
Income from continuing operations | ||||
EBIT | $79.24 | -$540.75 | $2668.77 | |
Income tax expense | $69.02 | -$235.45 | -$221.8 | $957.33 |
Interest expense | $93.8 | |||
Net income | ||||
Net income | $165.93 | -$202.12 | -$190.4 | $2436.21 |
Income (for common shares) | $165.93 | -$202.12 | $2436.21 |
(in millions $) | 27 Mar 2023 | 31 Jan 2022 | 30 Dec 2020 | 30 Dec 2019 |
---|---|---|---|---|
Revenue | ||||
Total revenue | $18131.85 | $482.32 | $108.59 | |
Cost of revenue | $3137.09 | $704.36 | $243.83 | |
Gross Profit | $14994.76 | -$222.04 | -$135.24 | |
Operating activities | ||||
Research & development | $1609.92 | |||
Selling, general & administrative | $570.02 | $107.22 | $48.8 | |
Total operating expenses | $5743.34 | $808.13 | $290.11 | |
Operating income | $12388.52 | -$325.8 | -$181.52 | |
Income from continuing operations | ||||
EBIT | $12388.52 | -$325.8 | -$181.52 | |
Income tax expense | $3686.68 | -$161 | -$0.27 | |
Interest expense | -$2 | -$1.72 | ||
Net income | ||||
Net income | $9881.99 | $15.2 | -$179.06 | |
Income (for common shares) | $9881.99 | $15.2 | -$179.06 |
(in millions $) | 6 Nov 2023 | 7 Aug 2023 | 30 Jul 2023 | 27 Mar 2023 |
---|---|---|---|---|
Net income | $165.93 | -$202.12 | $2436.21 | |
Operating activities | ||||
Depreciation | $40.87 | $33.76 | $38.91 | |
Business acquisitions & disposals | ||||
Stock-based compensation | ||||
Total cash flows from operations | $732.89 | $4658.79 | $2022.56 | |
Investing activities | ||||
Capital expenditures | -$145.06 | -$328.16 | -$171.16 | |
Investments | ||||
Total cash flows from investing | -$1187.2 | -$2430.49 | -$3027.2 | -$157.26 |
Financing activities | ||||
Dividends paid | ||||
Sale and purchase of stock | ||||
Net borrowings | -$16664.5 | -$16879.9 | -$14794.7 | |
Total cash flows from financing | -$308.42 | -$172.53 | -$454.7 | -$190.39 |
Effect of exchange rate | $64.1 | |||
Change in cash and equivalents | $13943.45 | $15038.35 | $291.5 | $14533.37 |
(in millions $) | 27 Mar 2023 | 30 Mar 2022 | 30 Dec 2020 | 30 Dec 2019 |
---|---|---|---|---|
Net income | $9881.99 | $10477.47 | $15.2 | -$179.06 |
Operating activities | ||||
Depreciation | $129.15 | $76.55 | $38.74 | $33.9 |
Business acquisitions & disposals | ||||
Stock-based compensation | ||||
Total cash flows from operations | $14221.54 | $905.69 | -$13.47 | -$198.54 |
Investing activities | ||||
Capital expenditures | -$380.54 | -$156.77 | -$66.03 | -$38.59 |
Investments | ||||
Total cash flows from investing | -$36.97 | -$576.27 | -$144.85 | -$77.11 |
Financing activities | ||||
Dividends paid | ||||
Sale and purchase of stock | ||||
Net borrowings | -$14794.7 | -$1920.51 | $141.72 | $7.94 |
Total cash flows from financing | -$1486.63 | $95.89 | $894.73 | $383.29 |
Effect of exchange rate | -$45.34 | $0.02 | ||
Change in cash and equivalents | $12663.78 | $384.53 | $691.06 | $107.65 |
BioNTech stock target cut to $91 from $100 by Goldman Sachs By Investing.com
Investing.com
21 Mar 2024
|
BioNTech Touts Its Oncology Shift After Reporting Disappointing Fourth Quarter Financials
Benzinga via Yahoo Finance
20 Mar 2024
|
BioNTech Se (BNTX) Q4 2023 Earnings Call Transcript
Motley Fool via Yahoo Finance
20 Mar 2024
|
Why Moderna Shares Are Falling - Moderna (NASDAQ:MRNA)
Benzinga
20 Mar 2024
|
Why Is BioNTech Stock Trading Lower On Wednesday? - BioNTech (NASDAQ:BNTX)
Benzinga
20 Mar 2024
|
BioNTech stock slips after Q4 results (NASDAQ:BNTX)
Seeking Alpha
20 Mar 2024
|
BioNTech Q4 earnings: COVID franchise to drive cash in 2024
Invezz
20 Mar 2024
|
BioNTech names new chief commercial officer ahead of launches
Investing.com
20 Mar 2024
|
Will Weakness in BioNTech SE's (NASDAQ:BNTX) Stock Prove Temporary Given Strong Fundamentals?
Simply Wall St. via Yahoo Finance
12 Mar 2024
|
12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds
Insider Monkey via Yahoo Finance
9 Mar 2024
|
Market cap | N/A |
---|---|
Enterprise value | N/A |
Shares outstanding | N/A |
Revenue | $5.88B |
---|---|
EBITDA | N/A |
EBIT | N/A |
Net Income | $2.21B |
Revenue Q/Q | -72.07% |
Revenue Y/Y | -60.50% |
P/E ratio | N/A |
---|---|
EV/Sales | N/A |
EV/EBITDA | N/A |
EV/EBIT | N/A |
P/S ratio | N/A |
P/B ratio | N/A |
Book/Share | N/A |
Cash/Share | N/A |
EPS | N/A |
---|---|
ROA | 9.49% |
ROE | N/A |
Debt/Equity | 0.15 |
---|---|
Net debt/EBITDA | N/A |
Current ratio | 10.37 |
Quick ratio | 10.14 |